Servi­er ex­pands Tib­so­vo la­bel with first com­bi­na­tion OK in a rare form of AML

Just over a year af­ter Servi­er shelled out near­ly $2 bil­lion to pick up Agios’ on­col­o­gy port­fo­lio — in­clud­ing the acute myeloid leukemia drug Tib­so­vo — the French phar­ma has scored an ap­proval in com­bi­na­tion with a com­mon­ly used chemother­a­py.

Servi­er se­cured an ap­proval on Thurs­day for Tib­so­vo to treat cer­tain new­ly di­ag­nosed IDH1-mu­tat­ed AML pa­tients along­side azac­i­ti­dine, which is sold by Bris­tol My­ers Squibb un­der the brand name Vi­daza.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.